<DOC>
	<DOCNO>NCT01258348</DOCNO>
	<brief_summary>The purpose study determine safe dose LY573636-sodium give combination sunitinib patient metastatic Renal Cell Carcinoma ( RCC ) determine side effect may associate LY573636-sodium sunitinib combination patient population . The tumor response rate also assess .</brief_summary>
	<brief_title>A Phase 1b Trial Patients With Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients must histologically confirm diagnosis metastatic RCC Patients must receive prior treatment cytotoxicbased chemotherapy regimen Patients must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) guideline Have adequate hematologic , hepatic renal function Have serum albumin level great equal 3.0 g/L Patients reproductive potential use medically approve contraceptive precaution trial 6 month follow last dose study drug Exhibit patient compliance geographic proximity allow adequate followup Have give write informed consent approve Lilly ethical review board ( ERB ) /institutional review board ( IRB ) govern site Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy , investigational therapy , least 4 week ( 6 week mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy ( except alopecia ) . Patients receive wholebrain radiation must wait 90 day start study therapy Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Have receive prior cytotoxic chemotherapybased systemic therapy metastatic RCC Have follow within 12 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure ( CHF ) , cerebrovascular accident , transient ischemic attack , pulmonary embolism Ongoing cardiac arrhythmia great New York Health Association Class II ( Protocol Attachment JZAI.4 ) , atrial fibrillation grade , prolongation QTc interval great 450 msec male great 470 msec female Have uncontrolled hypertension ( great 150/100 mm Hg despite optimal medical therapy ) , history poor compliance antihypertensive treatment Patients documented central nervous system leptomeningeal metastasis ( brain metastasis ) time study entry . Patients sign symptom neurological compromise appropriate radiographic imaging perform study entry Patients serious concomitant OR preexisting disorder , include active bacterial , fungal , viral infection , incompatible study ( discretion investigator ) Patients receive warfarin therapy treatment venous thrombosis prothrombotic condition Patients second primary malignancy could affect interpretation result . NOTE : Patients adequately treat carcinoma skin ( exclude melanoma ) patient prior history malignancy diseasefree great 2 year eligible Patients previously complete withdrawn study study investigate LY573636 Patients previously receive sunitinib Patients unable swallow capsule Patients require concomitant use potent CYP3A4 inducer inhibitor Women pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>